First in new class of diabetes drugs launched

Tirzepatide (Mounjaro) is the first dual GIP/GLP-1 receptor agonist to be launched in the UK.

by Chloe Harman

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days

Sign Up